Staccato Loxapine in Agitated Patients With Schizophrenia

Study Overview
=================
Brief Summary
-----------------
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients

Detailed Description
-----------------
This is an in-clinic, multi-center, randomized, double-blind, placebo-controlled study of 2 dose levels of Staccato Loxapine, 5 and 10 mg. Patients may receive up to 3 doses of study drug in a 24-hour period, depending on their clinical status. The primary endpoint is the change from baseline in the PANSS (Positive and Negative Symptom Scale) Excited Component (also known as PEC) score, performed at 2 hours after the first dose.

Official Title
-----------------
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Schizophrenic Patients With Agitation

Conditions
-----------------
Patients With Schizophrenia and Acute Agitation

Intervention / Treatment
-----------------
* Drug: Inhaled loxapine 5 mg
* Drug: Inhaled loxapine 10 mg
* Drug: Inhaled placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female adult patients with schizophrenia and acute agitation Exclusion Criteria: Agitation caused primarily by acute intoxication History of drug or alcohol dependence Treatment with benzodiazepines or other hypnotics within 4 hours prior to study drug administration

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Inhaled Loxapine 5 mg<br>Inhaled Loxapine 5 mg, may repeat x 1 or 2 after 2 hours | Drug: Inhaled loxapine 5 mg<br>* Inhaled loxapine 5 mg<br>* Other names: ADASUVE;|
| Experimental: Inhaled Loxapine 10 mg<br>Inhaled Loxapine 10 mg, may repeat x 1 or 2 after 2 hours | Drug: Inhaled loxapine 10 mg<br>* Inhaled loxapine 10 mg<br>* Other names: ADASUVE;|
| Placebo Comparator: Inhaled placebo<br>Inhaled Loxapine placebo, may repeat x 1 or 2 after 2 hours | Drug: Inhaled placebo<br>* Inhaled placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in PANSS-EC From Baseline | The Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (min) to 7 (max). The PANSS-EC, the sum of these 5 subscales, thus ranges from 5 to 35. Individuals were eligible if they had a PANSS-EC of ≥14 (out of 35) and a score ≥4 (out of 7) on at least 1 of the 5 items. | Baseline and 2 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Global Impression-Improvement (CGI-I) Score | Clinical Global Impression- Improvement (CGI-I) scores ranged from 1 to 7: 0=not assessed (missing), 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. | Baseline and 2 hours | 
| CGI-I Responders | Frequency of response based on the CGI-I (defined as achieving a CGI-I score of 1 or 2 at 2 hours after administration of the inhalation) | Baseline and 2 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
schizophrenia, agitation, inhaled loxapine, ADASUVE